Abera has developed a unique vaccine platform based on Gram-negative bacteria and derived Outer Membrane Vesicles (OMVs) that can be decorated on the surface with multiple antigens of choice at a high density. Abera’s platforms have several unique characteristics as explained on the right.

Abera’s display technology allows the simultaneous surface expression of multiple different antigens per bacterium or derived membrane vesicle. Multivalency is an important feature in obtaining protection against many infectious diseases. It also allows the generation of broadly protecting vaccines that induce immunity to multiple pathogens or pathogen variants at the same time.

Abera’s bacterial-based platforms, Bera-D and Bera-V, have intrinsic adjuvant activity. This results in strong stimulation of both humoral and cellular immune responses.

Needle_free

Abera’s vaccine platforms can be administered nasally or orally and are thus ideally suited to induce not only systemic but also local mucosal responses to prevent transmission of pathogens. This creates a strong advantage compared to injected vaccines as approximately 80 percent of infectious diseases spread via the mucosa where a majority of the body’s immune system is concentrated. In addition, needle-free administration has a lower demand for trained medical personnel and equipment, which makes it more cost-efficient compared to injection of the vaccine.

Current vaccines are expensive due to complex manufacturing processes. In contrast, Abera’s bacterial-based vaccines can be designed and manufactured in 14-30 days. The platform enables production of large quantities of the vaccine at a low-cost through a simple fermentation process.